This case was last updated from U.S. District Courts on 06/08/2021 at 08:30:11 (UTC).

PURDUE PHARMA, LP et al v. Collegium Pharmaceutical, Inc.

Case Summary

On April 09, 2021, Purdue Pharma L.P., Purdue Pharmaceuticals L.P., and Rhodes Technologies (collectively, “Purdue'' or “Plaintiffs”), represented by Christopher M. Morrison of Jones Day (Boston), filed an intellectual property lawsuit against Collegium Pharmaceutical, Inc. (“Collegium” or “Defendant”), seeking a judgement, permanent enjoinment and damages for allegedly unlawfully infringing the process for preparing oxycodone compositions. This case was filed in the U.S. District Court for the District of Massachusetts with Judge F. Dennis Saylor, IV presiding. 

The Plaintiff has claimed that “Purdue is the lawful owner of all right, title, and interest in the ’434 patent, entitled “process for preparing oxycodone compositions,” including all right to sue and to recover for past infringement thereof, which patent is listed in the FDA’s Orange Book as covering the drug OxyContin, which is the subject of approved NDA No. 022272. The ’434 patent was duly and legally issued on September 10, 2019, naming Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, and Robert Kupper as the inventors.”

In their complaint, the Plaintiffs alleged that, “Defendant has infringed the ’434 patent. The ’434 patent is listed in the FDA Approved Drug Products with Therapeutic Equivalence. Evaluations (“Orange Book”) as covering Purdue’s OxyContin® (oxycodone hydrochloride) (“OxyContin”), an extended-release pain medication. Collegium has infringed the ’434 patent under 35 U.S.C. § 271(e)(2)(A) by filing the Collegium NDA on the Collegium NDA Products and under 35 U.S.C. §§ 271(a), (b), (c), and (g) by actual marketing of the Collegium NDA Products. Upon information and belief, Collegium submitted Collegium’s NDA to the FDA under § 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355(b)(2)), seeking approval to engage in the commercial manufacture, use, sale, offer for sale, or importation of the Collegium NDA Products. On or about April 26, 2016, the FDA issued its final approval of Collegium’s NDA based on Collegium’s filings as of that date. On June 20, 2016, Collegium issued a press release announcing the commercial launch of the Collegium NDA Products.”

The Plaintiffs further alleged that, “Collegium has begun commercial manufacture of the Collegium NDA Products, has begun offering for sale and selling the Collegium NDA Products, and continues to manufacture (or have manufactured), offer for sale, sell, and distribute the Collegium NDA Products, including in this district. After having already begun marketing the Collegium NDA Products, on or about October 4, 2016, Collegium filed a supplemental application relating to Collegium’s NDA (“Collegium’s sNDA”). On or about November 6, 2017, the FDA issued its final approval of Collegium’s sNDA.  On information and belief, Collegium has marketed the Collegium NDA Products according to Collegium’s sNDA”.

There are two claims for relief laid down by the Plaintiffs. The first claim is that Collegium’s filing of its NDA constitutes an alleged infringement of the ’434 Patent. The second claim is that Collegium’s marketing of the Collegium NDA products allegedly infringes, and has infringed, the’434 Patent. 

In their prayer for relief, the Plaintiffs have requested the court to adjudge that Collegium has infringed, and that Collegium’s commercial sale, offer for sale, use, manufacture, and/or importation of the Collegium NDA Products has infringed, induced infringement of, and/or contributed to the infringement of the ’434 patent, preliminarily and permanently enjoining, pursuant to 35 U.S.C. §§ 271(e)(4)(B) and 283 and Rule 65, Fed. R. Civ. P, and awarding, pursuant to 35 U.S.C. §§ 271(e)(4)(C) and 284, damages to Purdue. 

This case summary may not reflect the current position of the parties to this litigation or the status of this case. Sign up to view the latest case updates and court documents.



Case Details Parties Documents Dockets

 

Case Details

  • Case Number:

    1:21-CV-10598

  • Filing Date:

    04/09/2021

  • Case Status:

    Pending - Other Pending

  • Case Type:

    Intellectual Property - Patent

Judge Details

Presiding Judge

F. Dennis Saylor, IV

 

Party Details

Plaintiffs

PURDUE PHARMA, LP

Rhodes Technologies

Purdue Pharmaceuticals L.P.

Defendant

Collegium Pharmaceutical, Inc.

Attorney/Law Firm Details

Plaintiff Attorney

Christopher M. Morrison

Attorney at Jones Day (Bos)

100 High Street, 21St Flr.

Boston, MA 02110

Defendant Attorneys

Jacob M. Holdreith

Attorney at Robins, Kaplan LLP

2800 Lasalle Plaza, 800 Lasalle Avenue

Minneapolis, MN 55402

Ellen K. Levish

Attorney at Robins Kaplan, LLP

800 Lasalle Avenue, Suite 2800, 2800 Lasalle Plaza

Minneapolis, MN 55402

Oren D. Langer

Attorney at Robins Kaplan LLP

601 Lexington Avenue, Suite 3400

New York, NY 10022

Emily J. Tremblay

Attorney at Robins Kaplan, LLP

800 Lasalle Avenue, Suite 2800, 2800 Lasalle Plaza

Minneapolis, MN 55402

Christopher A. Pinahs

Attorney at Robins Kaplan LLP

800 Lasalle Avenue, 2800 Lasalle Plaza

Minneapolis, MN 55402

Kelsey J McElveen

Attorney at Robins Kaplan, LLP

Christopher P. Sullivan

Attorney at Robins, Kaplan, Miller & Ciresi L.L.P.

800 Boylston Street, 25Th Floor

Boston, MA 02199-8001

 

Court Documents

12 #6

Affidavit Certificate of Oren Langer

12 #5

Affidavit Certificate of Kelsey McElveen

12 #4

Affidavit Certificate of Jacob Holdreith

12 #3

Affidavit Certificate of Emily Tremblay

12 #2

Affidavit Certificate of Ellen Levish

12 #1

Affidavit Certificate of Christopher Pinahs

#12

#11

#10

#8

#7

#5

3 #1

Category Form

#3

2 #1

Exhibit Scheduling Order

#2

10 More Documents Available
View All Documents

 

Docket Entries

  • 05/12/2021
  • View Court Documents

  • Docket(#13) Chief Judge F. Dennis Saylor, IV: ELECTRONIC ORDER entered ALLOWING #12 Motion for Leave to Appear Pro Hac Vice Added Christopher A. Pinahs, Ellen K. Levish, Emily J. Tremblay, Jacob M. Holdreith, Kelsey J. McElveen and Oren D. Langer. Attorneys admitted Pro Hac Vice must register for electronic filing if the attorney does not already have an ECF account in this district. To register go to the Court website at www.mad.uscourts.gov. Select Case Information, then Electronic Filing (CM/ECF) and go to the CM/ECF Registration Form. (Vieira, Leonardo) (Entered: 05/12/2021)

    [+] Read More [-] Read Less
  • 05/11/2021
  • View Court Documents

  • Docket(#12) MOTION for Leave to Appear Pro Hac Vice for admission of Christopher Pinahs, Ellen Levish, Emily Tremblay, Jacob Holdreith, Kelsey McElveen, Oren Langer Filing fee: $ 600, receipt number 0101-8769362 by Collegium Pharmaceutical, Inc.. (Attachments: #1 Affidavit Certificate of Christopher Pinahs, #2 Affidavit Certificate of Ellen Levish, #3 Affidavit Certificate of Emily Tremblay, #4 Affidavit Certificate of Jacob Holdreith, #5 Affidavit Certificate of Kelsey McElveen, #6 Affidavit Certificate of Oren Langer)(Sullivan, Christopher) (Entered: 05/11/2021)

    [+] Read More [-] Read Less
  • 05/07/2021
  • View Court Documents

  • Docket(#11) MEMORANDUM in Support re #10 MOTION to Dismiss Complaint Alleging Infringement of U.S. Patent No. 10,407,434 filed by Collegium Pharmaceutical, Inc.. (Sullivan, Christopher) (Entered: 05/07/2021)

    [+] Read More [-] Read Less
  • 05/07/2021
  • View Court Documents

  • Docket(#10) MOTION to Dismiss Complaint Alleging Infringement of U.S. Patent No. 10,407,434 by Collegium Pharmaceutical, Inc..(Sullivan, Christopher) (Entered: 05/07/2021)

    [+] Read More [-] Read Less
  • 04/28/2021
  • View Court Documents

  • Docket(#9) Chief Judge F. Dennis Saylor, IV: ELECTRONIC ORDER entered granting in part and denying in part #7 MOTION for Extension of Time to May 14, 2021 to File Response/Reply. Defendant has until 5/7/21 to file Response/Reply. (McKillop, Matthew) (Entered: 04/28/2021)

    [+] Read More [-] Read Less
  • 04/26/2021
  • View Court Documents

  • Docket(#8) Opposition re #7 MOTION for Extension of Time to May 14, 2021 to File Response/Reply as to #1 Complaint, filed by PURDUE PHARMA, LP, Purdue Pharmaceuticals L.P., Rhodes Technologies. (Morrison, Christopher) (Entered: 04/26/2021)

    [+] Read More [-] Read Less
  • 04/22/2021
  • View Court Documents

  • Docket(#7) MOTION for Extension of Time to May 14, 2021 to File Response/Reply as to #1 Complaint, by Collegium Pharmaceutical, Inc..(Sullivan, Christopher) (Entered: 04/22/2021)

    [+] Read More [-] Read Less
  • 04/21/2021
  • View Court Documents

  • Docket(#6) Chief Judge F. Dennis Saylor, IV: ELECTRONIC ORDER entered granting #2 Motion to Consolidate Cases (Halley, Taylor) (Entered: 04/21/2021)

    [+] Read More [-] Read Less
  • 04/12/2021
  • View Court Documents

  • Docket(#5) Summons Issued as to Collegium Pharmaceutical, Inc.. Counsel receiving this notice electronically should download this summons, complete one for each defendant and serve it in accordance with Fed.R.Civ.P. 4 and LR 4.1. Summons will be mailed to plaintiff(s) not receiving notice electronically for completion of service. (Pacho, Arnold) (Entered: 04/12/2021)

    [+] Read More [-] Read Less
  • 04/12/2021

  • Docket(#4) ELECTRONIC NOTICE of Case Assignment. Chief Judge F. Dennis Saylor, IV assigned to case. If the trial Judge issues an Order of Reference of any matter in this case to a Magistrate Judge, the matter will be transmitted to Magistrate Judge M. Page Kelley. (Finn, Mary) (Entered: 04/12/2021)

    [+] Read More [-] Read Less
  • 04/09/2021
  • View Court Documents

  • Docket(#3) Civil Cover Sheet & Category Sheet by PURDUE PHARMA, LP, Purdue Pharmaceuticals L.P., Rhodes Technologies. (Attachments: #1 Category Form)(Morrison, Christopher) (Entered: 04/09/2021)

    [+] Read More [-] Read Less
  • 04/09/2021
  • View Court Documents

  • Docket(#2) Joint MOTION to Consolidate Cases with 15-CV-13099-FDS by PURDUE PHARMA, LP, Purdue Pharmaceuticals L.P., Rhodes Technologies. (Attachments: #1 Exhibit Scheduling Order)(Morrison, Christopher) (Entered: 04/09/2021)

    [+] Read More [-] Read Less
  • 04/09/2021
  • View Court Documents

  • Docket(#1) COMPLAINT against Collegium Pharmaceutical, Inc. Filing fee: $ 402, receipt number 0101-8721229 (Fee Status: Filing Fee paid), filed by PURDUE PHARMA, LP, Purdue Pharmaceuticals L.P., Rhodes Technologies. (Attachments: #1 Exhibit US Patent No. 10,407,434)(Morrison, Christopher) (Entered: 04/09/2021)

    [+] Read More [-] Read Less

Why is this public record being published online?

UniCourt uses cookies to improve your online experience, for more information please see our Privacy Policy. By continuing to use this website, you agree to UniCourt’s General Disclaimer, Terms of Service, Cancellation and Refund Policy, Privacy Policy, and Public Records Policy. If you do not agree with these terms, then do not use our website and/or services.